Johnson & Johnson (JNJ)
Can J&J's MedTech Business Rebound in Q3 After Q2 Slowdown?
J&J's MedTech faces Abiomed and competitive pressures, but Vision, Orthopedics and Surgery could drive a stronger second half.
Johnson & Johnson (JNJ) Earnings Expected to Grow: Should You Buy?
Johnson & Johnson (JNJ) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Johnson & Johnson or Procter & Gamble: If I Could Only Own 1 Dividend King for 20 Years, This Is It
Both Dividend Kings trade at nearly identical valuations, so the real question becomes which one can actually keep raising its payout for two decades without flinching. The answer comes down to three factors most investors overlook entirely.
Johnson & Johnson (JNJ) Stock Drops Despite Market Gains: Important Facts to Note
Johnson & Johnson (JNJ) closed at $252.83 in the latest trading session, marking a -1.25% move from the prior day.
J&J's Innovative Medicine Segment in Q3: Key Growth Drivers to Watch
JNJ's Innovative Medicine segment is poised for another quarter of growth, with oncology and new launches helping offset Stelara's biosimilar-driven decline.
JNJ or MRK: One Dividend Is Built to Last, One Faces a Reckoning
Both JNJ and MRK have surged in 2026, but a looming patent cliff and a balance sheet loaded with acquisition debt mean one of these pharma dividends faces a reckoning that retirement investors cannot afford to ignore.
Why Johnson & Johnson (JNJ) is a Great Dividend Stock Right Now
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes?
Johnson & Johnson's psoriasis drug Icotyde could hit $4.5B in peak sales, BofA says
Johnson & Johnson (NYSE:JNJ)'s oral psoriasis drug Icotyde could reach $4.5 billion in peak sales, up from a previous $2.4 billion estimate, Bank of America said as it raised its price target on the company to $278 from $263. The broker now values estimated 2027 earnings excluding in-process research and development charges at 22 times, versus 20.33 previously, reflecting a sector rerating favoring defensive businesses.
Johnson & Johnson: Strong Catalysts, But I'm Staying At Hold
On October 13, Johnson & Johnson will report its results for the third quarter. As a reminder, its Q2 revenue grew 6.6% year-over-year to $25.31 billion, primarily due to the strong performance of the multiple myeloma portfolio and Tremfya. On September 23, J&J said modeling projected nearly fourfold longer median overall survival with Tecvayli+Darzalex Faspro versus SoC in patients with R/R multiple myeloma.
Johnson & Johnson's Next Growth Engine Is Taking Shape
Johnson & Johnson's oncology and immunology pipeline is firing on multiple cylinders, but a collapsing blockbuster drug and mounting litigation costs threaten to cancel out every gain. Here is whether the bull case or the headwinds win.
Want Bulletproof Dividend Income? These 3 Stocks Have Raised Payouts Through 8 Major Downturns
Three companies have written dividend checks through stagflation, financial collapse, and a global pandemic without missing a single annual raise, but the headwinds each faces right now will test whether history really does repeat.
Johnson & Johnson says Tremfya eases spinal pain in Phase 4 psoriatic arthritis study
Johnson & Johnson (NYSE:JNJ) said its Tremfya treatment significantly improved spinal pain and stiffness in adults with axial psoriatic arthritis in a Phase 4 study. The company said Tremfya met the study's primary endpoint at week 24, showing greater improvement than placebo on a disease activity measure that includes spinal pain and stiffness.
